CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oak Hill Bio (“Oak Hill”), a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases, today announced that members of its senior leadership team will participate in one-on-one meetings with investors at the upcoming Citi 17th Annual BioPharma Conference taking place on September 7-8, 2022, in Boston, MA.
For additional information or to schedule a one-on-one meeting with members of the Oak Hill management team, please contact your Citi representative.
About Oak Hill Bio
Oak Hill Bio is a clinical-stage neonatology and rare disease therapeutics company developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The company, which has operations in the United States and United Kingdom, was launched to develop a pipeline of six promising clinical-stage and preclinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited (“Takeda”). For more information on Oak Hill Bio, visit the company’s website at www.oakhillbio.com.
Contacts
Investors
Josh Distler
Oak Hill Bio
josh.distler@oakhillbio.com
Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
212-362-1200
Media
Chris Railey
Ten Bridge Communications
chris@tenbridgecommunications.com
617-834-0936